Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): A protocol for a randomised controlled feasibility study

BMJ Open

Volumn 7, Issue 8, 2017, Pages

  Oughton, Jamie B ^a   Poad, Heather ^a   Twiddy, Maureen ^a   Collinson, Michelle ^a   Hiley, Victoria ^a   Gordon, Kathryn ^a   Johnson, Mark ^b   Jain, Sunjay ^c   Noon, Aidan P ^d   Chahal, Rohit ^e   Simms, Matt ^f   Dooldeniya, Mohantha ^g   Koenig, Phillip ^h   Goodwin, Louise ^d   Brown, Julia M ^a   Catto, James W F ^d  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e BRADFORD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^f HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^g MID YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^h Airedale NHS Trust   (United Kingdom)

Author keywords

BCG; feasibility study; high risk non muscle invasive bladder cancer; radical cystectomy; RCT; surgical trial

Indexed keywords

BCG VACCINE; ANTINEOPLASTIC AGENT; IMMUNOLOGICAL ADJUVANT;

ADULT; AGED; ARTICLE; BCG VACCINATION; CANCER IMMUNOTHERAPY; CANCER RISK; CANCER SURGERY; CLINICAL PROTOCOL; CONTROLLED STUDY; CYSTECTOMY; FEASIBILITY STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON MUSCLE INVASIVE BLADDER CANCER; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; ADOLESCENT; BLADDER; BLADDER TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE EXACERBATION; DRUG EFFECTS; IMMUNOTHERAPY; INTRAVESICAL DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; PATHOLOGY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CYSTECTOMY; DISEASE PROGRESSION; FEASIBILITY STUDIES; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; RESEARCH DESIGN; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 85027404930     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2017-017913     Document Type: Article

References (50)

1. Chavan S, Bray F, Lortet-Tieulent J, et al. International variations in bladder cancer incidence and mortality. Eur Urol 2014;66:59-73.
2. Malmström PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus Bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56.
3. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-77.
4. Kulkarni GS, Hakenberg OW, Gschwend JE, et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 2010;57:60-70.
5. Thomas F, Noon AP, Rubin N, et al. Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer. Eur Urol 2013;63:145-54.
6. Sylvester RJ, van der Meiden AP, Lamm DL. Intravesical Bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964-70.
7. Mostafid AH, Palou Redorta J, Sylvester R, et al. Therapeutic options in high-risk non-muscle-invasive bladder cancer during the current worldwide shortage of bacille Calmette-Guérin. Eur Urol 2015;67:359-60. In Press.
8. Lamm DL, van der Meijden PM, Morales A, et al. Incidence and treatment of complications of Bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992;147:596-600.
9. van der Meijden AP, Sylvester RJ, Oosterlinck W, et al. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and treatment of Cancer Genito-Urinary group phase III trial. Eur Urol 2003;44:429-34.
10. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000;163:1124-9.
11. Lambert EH, Pierorazio PM, Olsson CA, et al. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. BJU Int 2007;100:33-6.
12. Schrier BP, Hollander MP, van Rhijn BW, et al. Prognosis of muscleinvasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol 2004;45:292-6.
13. Huguet J, Crego M, Sabaté S, et al. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol 2005;48:53-9.
14. Denzinger S, Fritsche HM, Otto W, et al. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol 2008;53:146-52.
15. Solsona E, Iborra I, Rubio J, et al. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour. BJU Int 2004;94:1258-62.
16. Shabsigh A, Korets R, Vora KC, et al. Defining early morbidity of radical cystectomy for patients with bladder Cancer using a standardized reporting methodology. Eur Urol 2009;55:164-76.
17. Hardt J, Filipas D, Hohenfellner R, et al. Quality of life in patients with bladder carcinoma after cystectomy: first results of a prospective study. Qual Life Res 2000;9:1-12.
18. Hautmann RE, Volkmer BG, Gust K. Quantification of the survival benefit of early versus deferred cystectomy in highrisk non-muscle invasive bladder cancer (T1 G3). World J Urol 2009;27:347-51.
19. Lane JA, Donovan JL, Davis M, et al. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. Lancet Oncol 2014;15:1109-18.
20. Stein JP, Penson DF. Invasive T1 bladder cancer: indications and rationale for radical cystectomy. BJU Int 2008;102:270-5.
21. NICE. Bladder Cancer Guidelines. Secondary bladder cancer guidelines. 2015. https://www. nice. org. uk/ guidance/ indevelopment/ gid- cgwave0600/ documents
22. Huddart RA, Hall E, Lewis R, et al. Life and death of spare (selective bladder preservation against radical excision): reflections on why the spare trial closed. BJU Int 2010;106:753-5.
23. Paramasivan S, Huddart R, Hall E, et al. Key issues in recruitment to randomised controlled trials with very different interventions: a qualitative investigation of recruitment to the SPARE trial (CRUK/07/011). Trials 2011;12:78.
24. Moynihan C, Lewis R, Hall E, et al. The patient deficit model overturned: a qualitative study of patients' perceptions of invitation to participate in a randomized controlled trial comparing selective bladder preservation against surgery in muscle invasive bladder cancer (SPARE, CRUK/07/011). Trials 2012;13:228.
25. Kaur G, Smyth RL, Williamson P. Developing a survey of barriers and facilitators to recruitment in randomized controlled trials. Trials 2012;13:218.
26. Fletcher B, Gheorghe A, Moore D, et al. Improving the recruitment activity of clinicians in randomised controlled trials: a systematic review. BMJ Open 2012;2:e000496.
27. Mills N, Blazeby JM, Hamdy FC, et al. Training recruiters to randomized trials to facilitate recruitment and informed consent by exploring patients' treatment pReferences. Trials 2014;15:323.
28. Mills N, Donovan JL, Wade J, et al. Exploring treatment pReferences facilitated recruitment to randomized controlled trials. J Clin Epidemiol 2011;64:1127-36.
29. Jn e GS, Ji E. World Health Organization classification of tumours. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon, France: IARC Press, 2004.
30. Histological typing of urinary bladder tumours. Geneva, Switzerland: World Health Organization, 1973.
31. Boustead GB, Fowler S, Swamy R, et al. Stage, grade and pathological characteristics of bladder cancer in the UK: British Association of Urological Surgeons (BAUS) urological tumour registry. BJU Int 2014;113:924-30.
32. National Cancer Intelligence Network Cancer e-atlas. http://www. ncin. org. uk/ cancer- information- tools/ eatlas
33. Thomas F, Rosario DJ, Rubin N, et al. The long-term outcome of treated high-risk nonmuscle-invasive bladder cancer: time to change treatment paradigm? Cancer 2012;118:5525-34.
34. Konety BR, Dhawan V, Allareddy V, et al. Impact of hospital and surgeon volume on in-hospital mortality from radical cystectomy: data from the health care utilization project. J Urol 2005;173:1695-700.
35. Fearon KC, Ljungqvist O, Von Meyenfeldt M, et al. Enhanced recovery after surgery: a consensus review of clinical care for patients undergoing colonic resection. Clin Nutr 2005;24:466-77.
36. Azhar RA, Bochner B, Catto J, et al. Enhanced recovery after urological surgery: a contemporary systematic review of outcomes, key elements, and research needs. Eur Urol 2016;70:176-87.
37. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337-43.
38. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.
39. Common Terminology Criteria for adverse events (CTCAE) Version 4.0: U.S Department of Health and Human Services, National Institute of Health, 2009. http:// evs. nci. nih. gov/ ftp1/ CTCAE/ CTCAE- 4. 03- 2010- 06- 14- QuickReference- 5x7. pdf
40. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205-13.
41. Edmondson AJ, Birtwistle JC, Catto JW, et al. The patients' experience of a bladder cancer diagnosis: a systematic review of the qualitative evidence. J Cancer Surviv 2017.
42. McDonald AM, Knight RC, Campbell MK, et al. What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. Trials 2006;7:9.
43. Kaur G, Hutchison I, Mehanna H, et al. Barriers to recruitment for surgical trials in head and neck oncology: a survey of trial investigators. BMJ Open 2013;3:e002625.
44. Wade J, Donovan JL, Lane JA, et al. It's not just what you say, it's also how you say it: opening the 'black box' of informed consent appointments in randomised controlled trials. Soc Sci Med 2009;68:2018-28.
45. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006;3:77-101.
46. Joffe H LY. Content and thematic analysis. Marks DF LY, ed. Research methods for clinical and Health Psychology. London: SAGE Publications Ltd, 2004.
47. Glaser BG, Strauss AL. The Discovery of Grounded Theory. Chicago: Aldine, 1967.
48. Charmay K. Constructing grounded theory: a practical guide through qualitative analysis. London: Sage, 2006.
49. Donovan J, Mills N, Smith M, et al. Quality improvement report: improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficult. BMJ 2002;325:766-70.
50. Realpe A, Adams A, Wall P, et al. A new simple six-step model to promote recruitment to RCTs was developed and successfully implemented. J Clin Epidemiol 2016;76:166-74.